US EditionDaewoong Pharmaceutical Presents Phase 2 Clinical Trial Poster on 'Bersiporocin' at ATS 2025, Highlights Global Patient Demographics
- On June 3, 2025, Daewoong Pharmaceutical shared interim findings from a global Phase 2 trial of Bersiporocin involving 102 idiopathic pulmonary fibrosis participants recruited across the United States and South Korea.
- The randomized, double-blind, placebo-controlled study aims to suppress fibrosis progression by selectively inhibiting collagen synthesis via PRS targeting amid a racially diverse population.
- Approximately 70% of participants received Bersiporocin with approved antifibrotics nintedanib or pirfenidone, while more than 50% of patients are Asian, enabling assessment across ethnic subgroups.
- Bersiporocin, granted Orphan Drug and Fast Track designations by the FDA, inhibits Prolyl-tRNA Synthetase to target fibrosis at its origin, with Professor Song stating the trial offers hope and diversity in treatment responses.
- Daewoong's CEO Seongsoo Park highlighted Bersiporocin as a pioneering antifibrotic treatment targeting the underlying cause of fibrosis and emphasized their dedication to further developing this initiative to transform global approaches to IPF therapy.
Insights by Ground AI
Does this summary seem wrong?
52 Articles
52 Articles
All
Left
6
Center
17
Right
6
Rutland Herald+51 Reposted by 51 other sources
Daewoong Pharmaceutical Presents Phase 2 Clinical Trial Poster on 'Bersiporocin' at ATS 2025, Highlights Global Patient Demographics
Ongoing Phase 2 study enrolling 102 patients in the U.S. and South Korea, with more than 50% of participants identified as Asian
Coverage Details
Total News Sources52
Leaning Left6Leaning Right6Center17Last UpdatedBias Distribution59% Center
Bias Distribution
- 59% of the sources are Center
59% Center
L 21%
C 59%
R 21%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
